Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 04, 2021 09:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Presents Preliminary Data from Ongoing CDX-527 Phase 1 Dose Escalation Trial at the 2021 ASCO Annual Meeting

HAMPTON, N.J., June 04, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced preliminary data from the Company’s Phase 1 dose escalation study of PD-L1xCD27 bispecific...
June 01, 2021 07:31 ET | Source: Celldex Therapeutics, Inc.

Celldex Announces Acceptance of Abstract for CDX-0159 Phase 1b Results in Inducible Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2021

HAMPTON, N.J., June 01, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing results from the Phase 1b study of CDX-0159 in patients with...
May 26, 2021 16:01 ET | Source: Celldex Therapeutics, Inc.

Celldex to Present at the Jefferies 2021 Virtual Healthcare Conference

HAMPTON, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that senior management will participate in a fireside chat at the Jefferies 2021 Virtual...
May 06, 2021 16:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Reports First Quarter 2021 Financial Results and Provides Corporate Update

HAMPTON, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update. ...
April 12, 2021 16:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Presents Promising Data from ILT4/PD-(L)1 Bispecific Antibody Program at AACR 2021

HAMPTON, N.J., April 12, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the presentation of promising data from the Company’s growing bispecific platform at the...
March 29, 2021 16:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2020 Results

HAMPTON, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and financial highlights for the fourth quarter and year ended December 31, 2020. ...
March 29, 2021 06:30 ET | Source: Celldex Therapeutics, Inc.

Celldex Reports 80% Complete Response Rate in Interim Data Update from Phase 1b study of CDX-0159 in Chronic Inducible Urticaria

--CDX-0159 generally well tolerated to date----Conference call to be held at 7:45 a.m. ET today-- HAMPTON, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today...
March 05, 2021 13:00 ET | Source: Celldex Therapeutics, Inc.

Celldex Therapeutics Announces Fireside Chat Presentation at the H.C. Wainwright Global Life Sciences Conference

HAMPTON, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the Company’s participation in a fireside chat at the H.C. Wainwright Global Life Sciences...
February 22, 2021 16:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Therapeutics to Expand Development of CDX-0159 into Prurigo Nodularis (PN)

--Dermatological indication characterized by chronic, intensely itchy nodules; mast cell activation believed to play an important role in amplifying chronic itch and neuroinflammation----Potential to...
February 22, 2021 08:01 ET | Source: Celldex Therapeutics, Inc.

Celldex Therapeutics to Present at 10th Annual SVB Leerink Global Healthcare Conference

HAMPTON, N.J., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that the Company will participate in a fireside chat at the 10th Annual SVB Leerink Global...